Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Extra Market Drug Price Survey Focal Point of Discussions towards FY2015 Tax Hike: Official
March 20, 2014
- MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
- MHLW to Draft Rules for Approval of Switch OTC Diagnostics in Meetings Open to the Public: Regulatory Reform Council
March 19, 2014
- MHLW OKs Additional Indications for Votrient, 2 Other Drugs
March 18, 2014
- FY2014 Reform to Strengthen Restrictions on Prescription of Multiple Psychotropic Drugs; Measures to Be Taken in Two Consecutive Reforms Due to Lack of Improvements
March 18, 2014
- PMDA to Up Review Fees for Generics, OTCs, Diagnostics in November
March 17, 2014
- Rules for Approval of Switch OTC Diagnostics to Be Finalized by PAFSC Committee by End of Year: PFSB Director General
March 17, 2014
- Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
- Opposition Lawmaker Raps Favorable Treatment for Special Zones in Mixed Healthcare
March 14, 2014
- Chuikyo Approves Promotion of Mixed Healthcare in National Strategic Special Zones, Reduction of Review Period by Half
March 14, 2014
- Committee for Assessment of Advanced Healthcare Services Holds 1st Meeting to Expedite Off-label Use of Anticancer Drugs under Senshin-iryo B program
March 13, 2014
- MHLW Notifies Prefectures of Rules on Online OTC Drug Sales
March 12, 2014
- Settlements Allowing Retroactive Modifications of Transaction Price Not Regarded as Settlements under New Price Cut Rule
March 12, 2014
- HPB’s Economic Affairs Division to Set Up Study Group to Monitor Progress of Roadmap to Promote Generic Drug Use
March 12, 2014
- Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
- PAFSC’s Committee on Blood Programs Approves Standard Prices of Raw Plasma to Rise in FY2014 Due to Hike in Consumption Tax
March 11, 2014
- PMDA Raises Caution on Teratogenicity of Keratosis Treatment Tigason, Urges Use Only in Serious Cases
March 11, 2014
- Kitasato Daiichi Cannot Secure Flu Vaccine Production Capacity for 20 Million People by State Project Deadline
March 10, 2014
- Opposition Lawmaker Throws Doubts on Key Premium Given to Dellegra
March 7, 2014
- MHLW to Issue Notification Asking Doctors to Refrain from Selecting “No Substitution” Checkbox When Writing Prescriptions
March 7, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…